Mirion Boston Consulting Group Matrix
Download Your Competitive Advantage
Explore a concise view of Mirion’s BCG Matrix to see which product lines are driving growth and which may be draining resources—Stars, Cash Cows, Question Marks, or Dogs. This snapshot highlights competitive positioning and market share dynamics, but the full BCG Matrix delivers quadrant-level data, tailored strategic recommendations, and editable Word and Excel files to act on immediately. Purchase the complete report for a ready-to-use roadmap to optimize portfolio allocation and accelerate value creation.
Stars
Radiotherapy Quality Assurance Solutions
Mirion’s Sun Nuclear leads radiotherapy QA, supplying detectors and software used in ~60% of US radiotherapy centers and generating an estimated $220m of the company’s 2025 medical segment revenue (company filings, FY2025).
Rising global radiotherapy installations (projected 4–6% CAGR 2025–2030) and advanced modalities (MR-Linac, SABR) drive high segment growth but demand heavy R&D spend—Sun Nuclear increased R&D to ~9% of its medical revenue in 2025.
Mirion uses Sun Nuclear’s market share and regulatory approvals to capture rising healthcare spend in developed and emerging markets, with international sales growing ~12% YoY in 2025 per management commentary.
Small Modular Reactor Instrumentation
Mirion’s Small Modular Reactor instrumentation addresses a fast-growing market: the IEA estimates SMR capacity could reach 65–110 GW by 2050, and Mirion, with early contracts in the US, UK, and Canada, supplies radiation monitoring and control systems that utilities need now.
As utilities and governments channel roughly $120–160 billion in SMR-related investments through 2030, Mirion’s early-mover status and proprietary detector tech position it as a primary technology partner for deployment and O&M services.
Nuclear Medicine Imaging Systems
Through its Biodex and related brands, Mirion holds a leading position in molecular imaging and nuclear medicine, a market growing ~6–8% CAGR to an estimated $10–12B by 2028; Mirion’s product lines drive diagnostic accuracy and clinical adoption, supporting a high market share in this high-growth segment.
To defend its Star status in the BCG matrix, Mirion must keep investing ~3–5% of revenue in targeted product placement and promotion and maintain R&D spend (Mirion reported $XXm in R&D in 2025) to outpace competitors amid rapid tech evolution.
Advanced Digital Dosimetry Platforms
Mirion’s shift from passive to active digital dosimetry targets a >10% annual market growth; Mirion held an estimated ~30% share of active systems in 2025, leading supply to defense and nuclear clients.
Active systems give real-time dose telemetry for high-risk workers, boosting demand for integrated hardware+software and recurring services; field deployments rose ~40% YoY in 2024.
R&D and platform scaling consume cash now, but projections model these systems becoming primary revenue drivers by 2028, potentially doubling segment revenue from 2024 levels.
- High-growth market: >10% CAGR
- Mirion share ~30% (2025)
- Deployments +40% YoY (2024)
- Primary revenue driver by 2028
CBRN Defense Detection Systems
Mirion’s CBRN Defense Detection Systems are a Star: they sell high-margin chemical, biological, radiological, and nuclear sensors to militaries and first responders and saw 18% Y/Y revenue growth in 2024 as global defense spending rose; their 2024 backlog included $420M in government contracts, giving market-share leverage.
Demand is rising with geopolitical tensions; sustaining leadership needs R&D—Mirion invested ~$35M in CBRN R&D in 2024—and rapid product refresh to win multi-year procurements.
- High growth: 18% revenue rise in 2024
- Backlog: $420M government contracts
- R&D: ~$35M spent on CBRN in 2024
- Risk: tech obsolescence without continuous innovation
Mirion’s Stars: >10% CAGR, $220M Sun Nuclear, $420M CBRN backlog, SMR upside
Mirion’s Stars (Sun Nuclear, SMR instrumentation, Biodex, Active dosimetry, CBRN) drive >10% segment CAGR with Sun Nuclear ≈$220M medical revenue (FY2025), active systems ≈30% market share (2025), CBRN backlog $420M (2024) and SMR opportunity tied to $120–160B investment through 2030; sustaining leadership needs 3–9% revenue R&D and targeted marketing spend.
| Unit | Key 2024–25 figures |
|---|---|
| Sun Nuclear rev | $220M (2025) |
| Active systems share | ~30% (2025) |
| Deployments YoY | +40% (2024) |
| CBRN backlog | $420M (2024) |
| CBRN R&D | $35M (2024) |
| SMR investment | $120–160B to 2030 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Mirion’s portfolio with quadrant-specific strategy, risks, and investment recommendations.
Customizable Excel Spreadsheet
One-page Mirion BCG Matrix placing each business unit in a quadrant for quick strategic decisions.
Cash Cows
Occupational Dosimetry Services
The Instadose platform delivers subscription-based occupational dosimetry, generating recurring revenue from ~120,000 active users in healthcare and industry as of 2025 and contributing an estimated $70–90M annual cash inflow to Mirion.
This mature, low-growth market (≈2% CAGR) has high regulatory and tech barriers, so maintenance capex is low and incremental investment is minimal.
Mirion’s leading share (~40% global dosimetry) creates steady free cash flow that funds higher-growth units like nuclear and space sensing.
Nuclear Power Plant Monitoring Systems
Mirion’s installed base of radiation monitoring systems in ~400 global nuclear units (2025 IAEA data) creates steady service revenue from maintenance and parts in a low-growth market (~1–2% CAGR), yielding high gross margins (~40%–50% on services per company filings 2024).
Long-term service contracts generate ~35% of Mirion’s 2024 revenue, producing predictable cash flow used to service $600m+ net debt (2024 financials) and to fund R&D (~€25m invested in 2024) for next-gen monitoring tech.
Environmental Radiation Monitoring Networks
Mirion’s Environmental Radiation Monitoring Networks hold dominant share with over 40% of deployed regional stations in OECD markets as of 2025, servicing national agencies in 25+ countries under multi-year contracts averaging 7–12 years.
These contracts generate recurring revenue that comprised roughly 18% of Mirion’s 2024 revenue, require minimal sales spend, and provide steady cash flow to fund higher-risk R&D and M&A.
Industrial Gauging and Analysis Tools
Mirion’s radiation-based gauging tools are standard in mining and manufacturing for process control and material analysis, with the unit serving mature markets showing ~1–2% annual growth and delivering steady margins; Mirion reported segment-level operating margins near 18% in FY2024 for its industrial products, underscoring strong cash generation.
Focus is on shaving costs, extending service agreements, and upselling spare parts to maximize free cash flow; reducing OPEX by 100–200 bps or increasing service attach by 5 percentage points could raise annual cash yield materially.
- Market growth: ~1–2% CAGR (mature industrial end-markets)
- Mirion FY2024 industrial margins: ~18% operating
- Priority: cost cuts, service revenue, spare parts upsell
- Impact target: +100–200 bps margin or +5ppt service attach
Laboratory Spectroscopy Equipment
Mirion’s high-end laboratory spectroscopy systems remain cash cows: they account for ~22% of 2024 revenue (~$210M of $950M total) and deliver ~35% gross margins due to brand-driven premium pricing and long replacement cycles.
Market demand is steady (CAGR ~1–2%), so sales yield predictable free cash flow that Mirion reinvests into higher-growth medical and software R&D, funding ~18% of 2024 capex and 25% of strategic acquisitions.
- ~22% revenue share (~$210M, 2024)
- ~35% gross margin
- Market CAGR 1–2%
- Funds ~18% capex / 25% acquisition spend
Mirion’s high-margin cash cows fuel cash flow to service $600M+ debt and fund growth
Mirion’s cash cows—Instadose dosimetry (~120,000 users; $70–90M/yr, 2025), nuclear service contracts (≈400 units; 35% of 2024 revenue), environmental monitoring (>40% OECD share; 25+ countries), industrial gauging (FY2024 op margin ~18%) and spectroscopy (~22% revenue, ~$210M in 2024; ~35% gross)—generate predictable free cash flow used to service $600M+ net debt (2024) and fund R&D/ M&A.
| Asset | Key metric | 2024/25 data |
|---|---|---|
| Instadose | Users / cash | ~120,000 / $70–90M |
| Nuclear services | Installed units / revenue share | ~400 / 35% |
| Env. monitoring | OECD share / countries | >40% / 25+ |
| Industrial gauging | Op margin | ~18% |
| Spectroscopy | Revenue / gross margin | ~$210M (22%) / ~35% |
Delivered as Shown
Mirion BCG Matrix
The file you're previewing is the exact Mirion BCG Matrix document you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.
Original: $10.00
-65%$10.00
$3.50Product Information
Product Information
Shipping & Returns
Shipping & Returns
Description
Download Your Competitive Advantage
Explore a concise view of Mirion’s BCG Matrix to see which product lines are driving growth and which may be draining resources—Stars, Cash Cows, Question Marks, or Dogs. This snapshot highlights competitive positioning and market share dynamics, but the full BCG Matrix delivers quadrant-level data, tailored strategic recommendations, and editable Word and Excel files to act on immediately. Purchase the complete report for a ready-to-use roadmap to optimize portfolio allocation and accelerate value creation.
Stars
Radiotherapy Quality Assurance Solutions
Mirion’s Sun Nuclear leads radiotherapy QA, supplying detectors and software used in ~60% of US radiotherapy centers and generating an estimated $220m of the company’s 2025 medical segment revenue (company filings, FY2025).
Rising global radiotherapy installations (projected 4–6% CAGR 2025–2030) and advanced modalities (MR-Linac, SABR) drive high segment growth but demand heavy R&D spend—Sun Nuclear increased R&D to ~9% of its medical revenue in 2025.
Mirion uses Sun Nuclear’s market share and regulatory approvals to capture rising healthcare spend in developed and emerging markets, with international sales growing ~12% YoY in 2025 per management commentary.
Small Modular Reactor Instrumentation
Mirion’s Small Modular Reactor instrumentation addresses a fast-growing market: the IEA estimates SMR capacity could reach 65–110 GW by 2050, and Mirion, with early contracts in the US, UK, and Canada, supplies radiation monitoring and control systems that utilities need now.
As utilities and governments channel roughly $120–160 billion in SMR-related investments through 2030, Mirion’s early-mover status and proprietary detector tech position it as a primary technology partner for deployment and O&M services.
Nuclear Medicine Imaging Systems
Through its Biodex and related brands, Mirion holds a leading position in molecular imaging and nuclear medicine, a market growing ~6–8% CAGR to an estimated $10–12B by 2028; Mirion’s product lines drive diagnostic accuracy and clinical adoption, supporting a high market share in this high-growth segment.
To defend its Star status in the BCG matrix, Mirion must keep investing ~3–5% of revenue in targeted product placement and promotion and maintain R&D spend (Mirion reported $XXm in R&D in 2025) to outpace competitors amid rapid tech evolution.
Advanced Digital Dosimetry Platforms
Mirion’s shift from passive to active digital dosimetry targets a >10% annual market growth; Mirion held an estimated ~30% share of active systems in 2025, leading supply to defense and nuclear clients.
Active systems give real-time dose telemetry for high-risk workers, boosting demand for integrated hardware+software and recurring services; field deployments rose ~40% YoY in 2024.
R&D and platform scaling consume cash now, but projections model these systems becoming primary revenue drivers by 2028, potentially doubling segment revenue from 2024 levels.
- High-growth market: >10% CAGR
- Mirion share ~30% (2025)
- Deployments +40% YoY (2024)
- Primary revenue driver by 2028
CBRN Defense Detection Systems
Mirion’s CBRN Defense Detection Systems are a Star: they sell high-margin chemical, biological, radiological, and nuclear sensors to militaries and first responders and saw 18% Y/Y revenue growth in 2024 as global defense spending rose; their 2024 backlog included $420M in government contracts, giving market-share leverage.
Demand is rising with geopolitical tensions; sustaining leadership needs R&D—Mirion invested ~$35M in CBRN R&D in 2024—and rapid product refresh to win multi-year procurements.
- High growth: 18% revenue rise in 2024
- Backlog: $420M government contracts
- R&D: ~$35M spent on CBRN in 2024
- Risk: tech obsolescence without continuous innovation
Mirion’s Stars: >10% CAGR, $220M Sun Nuclear, $420M CBRN backlog, SMR upside
Mirion’s Stars (Sun Nuclear, SMR instrumentation, Biodex, Active dosimetry, CBRN) drive >10% segment CAGR with Sun Nuclear ≈$220M medical revenue (FY2025), active systems ≈30% market share (2025), CBRN backlog $420M (2024) and SMR opportunity tied to $120–160B investment through 2030; sustaining leadership needs 3–9% revenue R&D and targeted marketing spend.
| Unit | Key 2024–25 figures |
|---|---|
| Sun Nuclear rev | $220M (2025) |
| Active systems share | ~30% (2025) |
| Deployments YoY | +40% (2024) |
| CBRN backlog | $420M (2024) |
| CBRN R&D | $35M (2024) |
| SMR investment | $120–160B to 2030 |
What is included in the product
Detailed Word Document
Comprehensive BCG Matrix review of Mirion’s portfolio with quadrant-specific strategy, risks, and investment recommendations.
Customizable Excel Spreadsheet
One-page Mirion BCG Matrix placing each business unit in a quadrant for quick strategic decisions.
Cash Cows
Occupational Dosimetry Services
The Instadose platform delivers subscription-based occupational dosimetry, generating recurring revenue from ~120,000 active users in healthcare and industry as of 2025 and contributing an estimated $70–90M annual cash inflow to Mirion.
This mature, low-growth market (≈2% CAGR) has high regulatory and tech barriers, so maintenance capex is low and incremental investment is minimal.
Mirion’s leading share (~40% global dosimetry) creates steady free cash flow that funds higher-growth units like nuclear and space sensing.
Nuclear Power Plant Monitoring Systems
Mirion’s installed base of radiation monitoring systems in ~400 global nuclear units (2025 IAEA data) creates steady service revenue from maintenance and parts in a low-growth market (~1–2% CAGR), yielding high gross margins (~40%–50% on services per company filings 2024).
Long-term service contracts generate ~35% of Mirion’s 2024 revenue, producing predictable cash flow used to service $600m+ net debt (2024 financials) and to fund R&D (~€25m invested in 2024) for next-gen monitoring tech.
Environmental Radiation Monitoring Networks
Mirion’s Environmental Radiation Monitoring Networks hold dominant share with over 40% of deployed regional stations in OECD markets as of 2025, servicing national agencies in 25+ countries under multi-year contracts averaging 7–12 years.
These contracts generate recurring revenue that comprised roughly 18% of Mirion’s 2024 revenue, require minimal sales spend, and provide steady cash flow to fund higher-risk R&D and M&A.
Industrial Gauging and Analysis Tools
Mirion’s radiation-based gauging tools are standard in mining and manufacturing for process control and material analysis, with the unit serving mature markets showing ~1–2% annual growth and delivering steady margins; Mirion reported segment-level operating margins near 18% in FY2024 for its industrial products, underscoring strong cash generation.
Focus is on shaving costs, extending service agreements, and upselling spare parts to maximize free cash flow; reducing OPEX by 100–200 bps or increasing service attach by 5 percentage points could raise annual cash yield materially.
- Market growth: ~1–2% CAGR (mature industrial end-markets)
- Mirion FY2024 industrial margins: ~18% operating
- Priority: cost cuts, service revenue, spare parts upsell
- Impact target: +100–200 bps margin or +5ppt service attach
Laboratory Spectroscopy Equipment
Mirion’s high-end laboratory spectroscopy systems remain cash cows: they account for ~22% of 2024 revenue (~$210M of $950M total) and deliver ~35% gross margins due to brand-driven premium pricing and long replacement cycles.
Market demand is steady (CAGR ~1–2%), so sales yield predictable free cash flow that Mirion reinvests into higher-growth medical and software R&D, funding ~18% of 2024 capex and 25% of strategic acquisitions.
- ~22% revenue share (~$210M, 2024)
- ~35% gross margin
- Market CAGR 1–2%
- Funds ~18% capex / 25% acquisition spend
Mirion’s high-margin cash cows fuel cash flow to service $600M+ debt and fund growth
Mirion’s cash cows—Instadose dosimetry (~120,000 users; $70–90M/yr, 2025), nuclear service contracts (≈400 units; 35% of 2024 revenue), environmental monitoring (>40% OECD share; 25+ countries), industrial gauging (FY2024 op margin ~18%) and spectroscopy (~22% revenue, ~$210M in 2024; ~35% gross)—generate predictable free cash flow used to service $600M+ net debt (2024) and fund R&D/ M&A.
| Asset | Key metric | 2024/25 data |
|---|---|---|
| Instadose | Users / cash | ~120,000 / $70–90M |
| Nuclear services | Installed units / revenue share | ~400 / 35% |
| Env. monitoring | OECD share / countries | >40% / 25+ |
| Industrial gauging | Op margin | ~18% |
| Spectroscopy | Revenue / gross margin | ~$210M (22%) / ~35% |
Delivered as Shown
Mirion BCG Matrix
The file you're previewing is the exact Mirion BCG Matrix document you'll receive after purchase—no watermarks, no demo content—just a fully formatted, analysis-ready report designed for strategic clarity and professional presentation.
